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Aim: A genetic variant has recently reached genome-wide significance for association 
with TNF-inhibitor response in rheumatoid arthritis patients. Here we undertake 
a replication study in a UK Caucasian population to test for association with TNF-
inhibitor response. Materials & methods: The genetic variant, rs3794271, located 
within the PDE3A–SLCO1C1 locus was analyzed for correlation with treatment 
response using both the EULAR classification criteria and absolute change in (Δ)
DAS28 scores as outcome measures. Results: Genotype data were available from 1750 
TNF-inhibitor treated individuals. However, no evidence for association was observed 
(EULAR: p = 0.91 and ΔDAS28: p = 0.93). Furthermore, no significant associations 
were observed upon stratification by the anti-TNF received (p > 0.05). Conclusion: 
In the largest replication cohort conducted to date, no evidence for association was 
observed.
First draft submitted: 30 October 2015; Accepted for publication: 7 March 2016; 
Published online: 16 May 2016
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Genome-wide association studies (GWAS) 
have proven highly successful in the iden-
tification of rheumatoid arthritis (RA) sus-
ceptibility loci; it was therefore hypothesized 
that this strategy would also prove success-
ful in the identification of genetic variants 
predictive of treatment response in RA. 
To date, six small-scale GWAS have been 
conducted investigating response to TNF-
inhibitor biologics [1–6], with little consis-
tency in the findings. However, a SNP at the 
PDE3A–SLCO1C1 locus on chromosome 
12 (rs3794271) correlating with EULAR 
response (p = 3.5 × 10-6) in a Danish GWAS 
(n = 196) [3] has since been replicated in a 
Spanish RA population (n = 315; p = 1.74 × 
10-5) [7]. On meta-analysis of both cohorts, 
the strength surpassed genome-wide signifi-
cance thresholds (p = 3.3 × 10-10) [7]. It was 
estimated that the SNP may account for 
10% of the variance observed in treatment 
response to TNF inhibitors, thereby poten-
tially possessing clinical utility (if used in an 
algorithm). It is important that further repli-
cation be attempted in order to confirm this 
association in other populations.
The aim of this research was, there-
fore, to replicate the genome-wide signifi-
cant genetic association observed at the 
PDE3A–SLCO1C1 locus in a larger sam-
ple cohort of UK Caucasian RA patients 
receiving a TNF-inhibitor biologic drug.
Materials & methods 
Patient selection
DNA samples from Caucasian patients with 
RA were selected from BRAGGSS, a pro-
spective longitudinal cohort study, recruit-
ing RA patients across the UK who are about 
to commence/currently receiving treatment 
with biologic drugs, described in detail pre-
viously [8]. Twenty-eight joint-count disease 
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activity scores (DAS28) using four variables (the num-
ber of tender and swollen joints, erythrocyte sedimen-
tation rate [ESR]/C-reactive protein [CRP] and patient 
global assessment score) are recorded prior-to and at 
3, 6 and 12 months thereafter [9]. The BRAGGSS 
study was approved by a multicenter ethics committee 
(COREC 04/Q1403/37).
Definition of treatment response
Response to treatment was assessed using two mea-
sures. First, using the EULAR response criteria at 3 
or 6 months following treatment, patients were clas-
sified into either non-responders (ΔDAS28 score ≤0.6 
or 0.6–1.2 and an end score of >5.1), good respond-
ers (ΔDAS28 score >1.2 and an end score of ≤3.2) or 
moderate responders (anything in-between). Second, 
absolute change in DAS28 scores (DAS28
3/6-month
 – 
DAS28
baseline
), a continuous variable, was also used to 
assess outcome.
Genotyping
Genetic data were extracted from six genome-wide 
genetic datasets (Affymetrix®, CA, USA; Illumina®, 
CA, USA). Per platform, sample quality control (QC) 
involved the removal of ethnic outliers and closely 
related individuals, while SNP QC involved the 
removal of SNPs with greater than 5% missing data, 
SNPs with Hardy–Weinberg p-value of <5.7 × 10-7 
and SNPs with minor allele frequencies (MAFs) less 
than 1%. The remaining SNPs were imputed using the 
1000 Genomes reference panel using the IMPUTE2 
software. SNPs with high imputation accuracy, in 
other words, information (INFO) score greater than 
0.9 were retained and a second round of QC using 
the above pipeline was performed. Finally, the SNPs 
 identified from these analyses were extracted.
Statistical analysis
The test for association between the PDE3A–SLCO1C1 
locus and response to TNF-inhibitor treatment was 
conducted using PLINK version 1.07 [10,11]. Power 
calculations were performed using Quanto (version 
2.4) [12].
The primary test for association was with EULAR 
response in a logistic regression model, excluding mod-
erate responders. Both univariate and multivariate 
models were assessed; the multivariate model included 
baseline DAS28, gender, baseline health assessment 
questionnaire (HAQ) scores and concurrent disease-
modifying anti-rheumatic drug (DMARD) used as 
covariates. Furthermore, in order to investigate any 
drug-specific associations, the analyses were repeated 
following  stratification by the TNF-inhibitor drug 
received.
Finally, SNP dosage data were correlated with 
absolute change in DAS28 scores (ΔDAS28) in linear 
regression models (both univariate and multivariate) 
and the analysis was repeated following stratification 
by the TNF-inhibitor drug received.
Results
Following QC and the exclusion of patients not receiv-
ing TNF-inhibitor biologics, 1750 Caucasian RA 
patients were available for association analysis. The 
current study had greater than 95% power to iden-
tify the same effect sizes as reported in the previously 
reported PDE3A–SLCO1C1 studies [3,7], assuming a 
minor allele frequency (MAF) of 0.40 for rs3794271 
at the 5% significance threshold. The baseline char-
acteristics for the cohort are shown in the table below 
(Table 1).
The PDE3A–SLCO1C1 variant, rs3794271, failed 
to genotype in less than 1% of individuals across the 
entire cohort; furthermore, the PDE3A–SLCO1C1 
variant was imputed with INFO scores greater than 
0.96. The minor G allele of rs3794271, in our study 
had a MAF of 0.40, which is comparable to the MAF 
reported by the 1000 Genomes project database for 
European populations (MAF: 0.36) and those reported 
by the Danish and Spanish cohorts (MAFs of 0.35 and 
0.34, respectively).
For the primary analysis, genotype frequencies for 
the PDE3A–SLCO1C1 variant, rs3794271, were com-
pared between EULAR non-responder (n = 359) and 
good responder (n = 646) patients only. However, no 
evidence for association was observed (Table 2). Strati-
fying the analyses by the drug taken showed no sig-
nificant associations (p > 0.05). Specifically, the mul-
tivariate p-values for the PDE3A–SLCO1C1 variant, 
rs3794271, in the etanercept (n = 323) and infliximab 
(n = 254) subgroups were 0.52 and 0.74, respectively.
For the secondary analysis of change in DAS28, gen-
otype data from 1750 patients were available for analy-
sis. Following linear regression, no significant associa-
tions with treatment response were observed (Table 2). 
Following stratification by the anti-TNF received, again 
no significant associations were observed (p > 0.05).
Discussion
In this large, well-powered replication cohort from 
the UK, no evidence for association between the 
PDE3A–SLCO1C1 variant, rs3794271 and response 
to TNF-inhibitor biologics was observed using either 
the EULAR response criteria or ΔDAS28 as outcome 
measures. This is in contrast to previous studies where 
statistically significant associations with EULAR 
response have been observed (PDE3A–SLCO1C1, 
p = 3.5 × 10-6 and p = 1.74 × 10-5; combined meta-
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analysis, p = 3.3 × 10-10) [3,7]; the strength surpassing 
genome-wide significance upon meta-analysis.
The current study of 1750 patients is by far the 
largest replication study conducted to date, resulting 
in adequate power (>95%) to detect the same effect 
sizes as previously reported. For comparison, the Dan-
ish and Spanish PDE3A–SLCO1C1 cohorts comprised 
196 and 315 RA patients, respectively, and were further 
reduced to 135 and 182 patients, respectively, following 
the exclusion of EULAR moderate responders.
A number of reasons could explain the discrepancy 
between the current study and the previously reported 
associations. First, the confounding variables accounted 
for within the current multivariate analysis [13] were 
not all accounted for in the previous studies; however, 
no significant associations were observed within the 
current univariate and multi variate models suggesting 
the confounding variables did not explain the differ-
ences. Second, the associations observed in the Dan-
ish and Spanish cohorts may be population specific. 
Third, of contrast to the previous reports, treatment 
response in the current study was assessed at two time-
points. 6 months (n = 1573) and 3 months (n = 177); as 
compared with the Danish PDE3A–SLCO1C1 cohort 
and Spanish cohort where response was assessed at 14 
and 12 weeks, respectively [3,7]. However, it has been 
reported that EULAR moderate and good respond-
ers peak following 12 weeks of treatment and remain 
relatively stable thereafter [14]. Further stratification by 
the assessment timepoint did not significantly alter the 
findings (p > 0.05; data not shown).
Furthermore, heterogeneity existed within the cur-
rent study as to how the DAS28 scores were calcu-
lated (by using either ESR or CRP within the DAS28 
Table 1. Baseline characteristics of the 1750 Caucasian rheumatoid arthritis patients analyzed in 
terms of treatment response.
Cohort characteristics Non-responders Moderate responders Good responders
Observations, n (%) 359 (20.5%) 745 (42.6%) 646 (36.9%)
Gender (F), n (%) 292 (81.3%) 587 (78.8%) 473 (73.2%)
Age at baseline (years), me (SD) 56.5 (11.53) 58 (10.96) 55.8 (11.67)
Concurrent DMARDs, n (%) 270 (75.2%) 580 (77.9%) 575 (89%)
Baseline DAS28, me (SD) 6.27 (1.12) 6.59 (0.92) 6.13 (0.88)
End-point DAS28, me (SD) 5.87 (1.17) 4.3 (0.77) 2.31 (0.65)
Change in DAS28, me (SD) -0.40 (1.02) -2.29 (0.85) -3.82 (1.01)
Baseline TJC, med (IQR) 15 (9–21) 16 (11–23) 15 (10–21)
Baseline SJC, med (IQR) 9 (5–14) 10 (6–15) 9.5 (6–14)
Baseline HAQ, med (IQR), n 2.13 (1.75–2.38), 327 2 (1.63–2.38), 693 1.88 (1.25–2.13), 609
Treated with infliximab, n (%) 119 (33.2%) 206 (27.7%) 136 (21.1%)
Smoking status, n (%)† 43 (15.52%) 85 (15.86%) 79 (17.48%)
Treated with adalimumab, n (%) 104 (29%) 188 (25.2%) 255 (39.5%)
Treated with etanercept, n (%) 118 (32.9%) 303 (40.7%) 205 (31.7%)
Treated with golimumab, n (%) 5 (1.4%) 11 (1.5%) 9(1.4%)
Treated with certolizumab, n (%) 13 (3.6%) 37 (5%) 41 (6.3%)
†Smoking status for current smokers (based upon the 1265 patients with smoking data available.
DAS28: Disease activity score in 28-joint; DMARD: Disease modifying anti-rheumatic drug; F: Female; HAQ: Health assessment 
questionnaire; IQR: Interquartile range; me: Mean; med: Median; SD: Standard deviation; SJC: Swollen joint count in 28-joint; TJC: Tender 
joint count in 28-joint.
Table 2. Summary statistics of the SNP under investigation for response with anti-TNF treatment.
 EULAR p-value; OR (95% CI) ΔDAS28 p-value; β-coefficient (95% CI)
SNP Univariate model Multivariate model Univariate model Multivariate model
rs3794271  
(PDE3A–SLCO1C1) 
0.91; 1.01 (0.84–1.22) 0.74; 1.04 (0.85–1.27) 0.93; -0.0047 (-0.11–0.10) 0.69; -0.0203 (-0.12–0.081)
Association analysis between anti-TNF response in UK Caucasian RA patients and genotype data for rs3794271 was performed using univariate and multivariate 
models. The resulting p-values were calculated using additive regression models.
OR: Odds ratio.
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calculation). Previous studies have suggested that 
CRP more accurately reflects inflammation, as ESR 
can be influenced by age, gender and ethnicity [15,16]. 
However, it has been demonstrated that use of either 
inflammatory marker generally results in classifying 
patients into the same EULAR phenotype with 82.4% 
agreement and where discrepancies did occur, they 
were moderate in magnitude [15]. Indeed, where both 
inflammatory markers were available within the cur-
rent study an overall agreement of 77.4% in classifying 
EULAR response was observed (similarly, discrepan-
cies were moderate in magnitude). Further analysis 
following stratification by the inflammatory marker 
utilized in the DAS28 calculation did not materially 
alter the  conclusions (data not shown).
Of note, two TNF inhibitors, certolizumab and 
golimumab, were included in the current study but 
not in either of the previous reports. However, as they 
represent a small proportion of the total cohort, 5.2 
and 1.43%, respectively, this is unlikely the reason for 
the lack of replication. Stratification by the anti-TNF 
received, resulted in non-significant associations for 
PDE3A–SLCO1C1 (p > 0.05), which is in contrast to 
the previously reported study by Acosta-Colman et al., 
which reported that infliximab and etanercept were 
driving the association with EULAR response [7].
Conclusion
In summary, the largest replication cohort tested 
to date has found no evidence for association of the 
PDE3A–SLCO1C1 locus with TNF-inhibitor response 
in a UK Caucasian RA population. The lack of asso-
ciation is disappointing given that this locus was the 
first to exceed genome-wide significance thresholds 
and has shown consistent evidence for association in 
two independent European cohorts.
Future perspective
Since the introduction of biological therapies, which 
have proven highly effective in the treatment of rheu-
matoid arthritis, the need for biomarkers predictive 
of treatment response has become even more press-
ing. However, as of yet, a single biomarker which 
can accurately predict treatment response has thus 
far alluded us; with these therapies prescribed on 
what is essentially a trial and error basis. Such an 
approach to prescribing biological therapies unsur-
prisingly therefore, results in a significant proportion 
of patients not responding satisfactorily to treatment. 
In the era of stratified medicine, various approaches 
are being adopted in the search for predictive bio-
markers, these include amongst others; genetic, 
transcriptomic and proteomic studies. However, it is 
becoming more apparent, that these individualized 
approaches will not be enough to guide treatment 
decisions. Rather, systems-based approaches which 
integrate genetic, transcriptomic, proteomic, clinical 
and demographic data into predictive algorithms are 
now being adopted and will most likely be used in 
clinical settings.
Executive summary
Biological therapies revolutionized the treatment of rheumatoid arthritis, however, currently there is not 
a biomarker capable of accurately predicting treatment
•	 Currently biologics are prescribed on a trial and error basis resulting in up to 40% of patients receiving them 
responding unsatisfactorily.
•	 Early and effective treatment is key in-order to optimize patient outcome and reduce/limit irreversible joint 
damage.
•	 Biologics are costly (costing ∼GB£10,000 per patient per year) and are associated with adverse events.
•	 There is therefore an urgent need to identify biomarkers predictive of response.
Previously, a genetic variant at the PDE3A–SLCO1C1 locus, rs3794271, had shown replicative evidence in 
two independent studies for association with treatment response
•	 The association reached genome-wide significance upon meta-analysis of the Spanish and Danish cohorts.
Replication in a large UK population of rheumatoid arthritis patients found no evidence for association
•	 Replication was conducted in 1750 UK rheumatoid arthritis patients using both the EULAR classification 
criteria and absolute changes in DAS28 scores (ΔDAS28) as outcome measures.
•	 However, we found no evidence to support the use of rs3794271 as a biomarker predictive of response to  
anti-TNF biologics (EULAR, p = 0.91; ΔDAS28, p = 0.93).
•	 Drug-specific effects were also investigated; however, similar observations were observed (i.e., no association 
as shown by a p-value > 0.05).
Conclusion
•	 In the largest replication cohort conducted to date, no evidence of association was found to support the use 
of rs3794271 as a clinically useful predictor of response to anti-TNF biologics in rheumatoid arthritis patients 
from the UK.
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